Magic mushroom compound takes on depression in major trial

NCT ID NCT06308653

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 29 times

Summary

This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) can safely reduce depression symptoms in adults with major depressive disorder. About 238 participants will receive either 25 mg psilocybin, a low 5 mg dose, or a placebo. Researchers will track changes in depression scores over 43 days and follow participants for a year to see how long any benefits last.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, MAJOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AIM Trials, LLC

    Plano, Texas, 75093, United States

  • Bronx Veterans Research Foundation at the James J. Peters VAMC

    The Bronx, New York, 10468, United States

  • Cedar Clinical Research

    Draper, Utah, 84020, United States

  • Cedar Clinical Research, Inc.

    Murray, Utah, 84107, United States

  • CenExel iResearch, LLC

    Decatur, Georgia, 30030, United States

  • Clinical Neuroscience Solutions Inc.

    Jacksonville, Florida, 32256, United States

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida, 32801, United States

  • Clinical Trials of Texas, LLC

    San Antonio, Texas, 78229, United States

  • Connecticut Mental Health Center, Yale University

    New Haven, Connecticut, 06519, United States

  • Emory University

    Atlanta, Georgia, 30329, United States

  • Global Medical Institutes, LLC; Princeton Medical Institute

    Princeton, New Jersey, 08540, United States

  • Great Lakes Clinical Trials

    Chicago, Illinois, 60640, United States

  • Innovative Clinical Research, Inc.

    Lauderhill, Florida, 33319, United States

  • Johns Hopkins School of Medicine, Center for Psychedelic and Consciousness Research

    Baltimore, Maryland, 21224, United States

  • Kadima Neuropsychiatry Institute

    La Jolla, California, 92037, United States

  • Mountain View Clinical Research

    Denver, Colorado, 80209, United States

  • NYU Clinical & Translational Science Institute

    New York, New York, 10016, United States

  • Pacific Neuroscience Institute (PNI) at Saint John's Physician Partners

    Santa Monica, California, 90404, United States

  • Preferred Research Partners, Inc.

    Little Rock, Arkansas, 72211, United States

  • Preferred Research Partners-NWA, LLC

    Fayetteville, Arkansas, 72703, United States

  • Psychedelic Science Institute

    Santa Monica, California, 90404, United States

  • Seattle Neuropsychiatric Treatment Center

    Bellevue, Washington, 98004, United States

  • Sunstone Medical PC

    Rockville, Maryland, 20850, United States

  • University of Alabama Clinical Research Unit

    Birmingham, Alabama, 35209, United States

  • University of New Mexico (UNM) Interdisciplinary Substance Use and Brain Injury (ISUBI) Center

    Albuquerque, New Mexico, 87106, United States

  • VA Nebraska Western Iowa Health Care System

    Omaha, Nebraska, 68105, United States

  • VA Portland Health Care System

    Vancouver, Washington, 98661, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • West LA VA Medical Center - Mental Health Department

    Los Angeles, California, 90073, United States

Conditions

Explore the condition pages connected to this study.